CN215461270U - Catheter - Google Patents
Catheter Download PDFInfo
- Publication number
- CN215461270U CN215461270U CN202022939601.2U CN202022939601U CN215461270U CN 215461270 U CN215461270 U CN 215461270U CN 202022939601 U CN202022939601 U CN 202022939601U CN 215461270 U CN215461270 U CN 215461270U
- Authority
- CN
- China
- Prior art keywords
- balloon
- main pipeline
- catheter
- channel
- joint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 claims abstract description 38
- 239000007788 liquid Substances 0.000 claims abstract description 36
- 210000002700 urine Anatomy 0.000 claims abstract description 16
- 238000000502 dialysis Methods 0.000 claims abstract description 15
- 239000012528 membrane Substances 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 230000002485 urinary effect Effects 0.000 claims description 16
- 230000000844 anti-bacterial effect Effects 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 229960002464 fluoxetine Drugs 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- 229960003500 triclosan Drugs 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 241000588770 Proteus mirabilis Species 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 3
- 239000004137 magnesium phosphate Substances 0.000 claims description 3
- 229960002261 magnesium phosphate Drugs 0.000 claims description 3
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 3
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 229960001790 sodium citrate Drugs 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 2
- 210000005077 saccule Anatomy 0.000 claims 1
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- -1 silver ions Chemical class 0.000 description 2
- 201000004538 Bacteriuria Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Images
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The utility model discloses a catheter, comprising: the urethral catheterization device comprises a main pipeline, wherein a first channel for urethral catheterization is arranged in the main pipeline; the first balloon is fixed on the outer wall of the main pipeline, and a second channel communicated with the first balloon is arranged in the main pipeline and used for conveying liquid medicine into the first balloon; and a first joint; wherein, the capsule wall of the first sacculus is a dialysis membrane for leading the liquid medicine to enter the human bladder through the dialysis action. This catheter, insert patient's bladder preset position with the one end of trunk line, the urine is derived through the first passageway in the trunk line, in addition, can be at any time to the liquid medicine of the relative high concentration of input in the first sacculus through first joint and second passageway, first sacculus adopts the dialysis membrane, the medicine passes through the dialysis and enters into in the bladder sustainability to realize the controllable and initiative release of medicine, the kind of medicine can be selected according to actual need with the input opportunity, this utility model is used for the medical supplies field.
Description
Technical Field
The utility model relates to the field of medical supplies, in particular to a catheter.
Background
The urinary catheter is one of the more common diagnosis and treatment means, and as an invasive operation, the use of the urinary catheter also increases the probability of urinary system infection of patients, and is the second infection type to respiratory tract infection. Of the hospital-acquired infections reported to date, 80% of urinary tract infections are associated with indwelling catheters and 20% are associated with the operation of urinary tract equipment by medical personnel, where the incidence of bacteriuria in patients who use catheters multiple times approaches 50%. Urinary tract infection related to the catheter is a common complication type of patients using the catheter, the clinical incidence rate of the urinary tract infection is high, and the bacterial species mainly comprise deisobacter proteus, escherichia coli, pseudomonas aeruginosa and the like.
In the related technology, the design and development of the catheter mainly take a three-cavity catheter as a main part, part of the catheter can be used for inputting liquid into a bladder so as to play a role in flushing the bladder, part of the catheter deposits a coating between a balloon of the catheter and a urine input port, and different medicines or factors are added into the coating so as to realize different functions, wherein the antibacterial factors comprise a silicon surface active agent, zinc ions, silver ions, chitosan and the like, the anti-deposition factors comprise heparin, natural proteins and related amino acid polymers, and the lubrication promoting factors comprise isocyanate modified vinyl pyrrolidone polymers, teflon and the like.
The antibacterial catheter coating is a disposable coating which is prepared in advance, the type of the medicine is single, the medicine or factors are passively released in the coating in one step, and the problem that the medicine resistance is easily generated by bacteria exists, so that the indwelling time is limited, the catheter needs to be replaced periodically, the service life of the catheter cannot be prolonged, and great pain is brought to patients.
SUMMERY OF THE UTILITY MODEL
The utility model aims to solve at least one of the technical problems in the prior art and provides a catheter which can realize the controllable and active release of medicines.
According to an embodiment of the utility model, there is provided a urinary catheter comprising:
the urethral catheterization device comprises a main pipeline, wherein a first channel for urethral catheterization is arranged in the main pipeline;
the first balloon is fixed on the outer wall of the main pipeline, and at least one second channel communicated with the first balloon is arranged in the main pipeline and used for conveying liquid medicines into the first balloon; and
at least one first connector connecting the respective second channels;
wherein, the capsule wall of the first sacculus is a dialysis membrane for leading the liquid medicine to enter the bladder of the human body through dialysis.
The catheter has at least the following beneficial effects: insert patient's bladder preset position with the one end of trunk line, the urine is derived through the first passageway in the trunk line, in addition, can input the liquid medicine of relative high concentration at any time to first sacculus through first joint and second passageway, and first sacculus adopts the dialysis membrane, and the medicine passes through the dialysis and persistently gets into in the bladder to realize the controllable and initiative release of medicine, the kind of medicine and input opportunity can be selected according to actual need.
According to the catheter provided by the embodiment of the utility model, different antibacterial liquid medicines are injected into the first balloon.
According to the urinary catheter, the antibacterial liquid medicine comprises at least one of triclosan, sodium citrate, fluoxetine and pyrazothion, wherein the triclosan is used for killing proteus mirabilis and pseudomonas aeruginosa, the sodium citrate is used for reducing the pH of urine and inhibiting the deposition of calcium carbonate and magnesium phosphate, and the fluoxetine and the pyrazothion are used for inhibiting the formation of bacterial films.
According to the catheter provided by the embodiment of the utility model, the catheter further comprises a second balloon, the second balloon is fixed on the outer wall of the main pipeline, a third channel communicated with the second balloon is arranged in the main pipeline and used for conveying gas or liquid into the second balloon, so that the second balloon is expanded and fixed in the bladder of a human body.
According to the urinary catheter of the embodiment of the utility model, the urinary catheter further comprises a second connector, and the second connector is connected with the third channel.
According to the urinary catheter, the pipe plugs for sealing are arranged at the liquid inlets of the first connector and the second connector.
According to the urinary catheter provided by the embodiment of the utility model, one end of the first channel is provided with the urine inlet, and the other end of the first channel is connected with the third connector which is used for being connected with the urine containing device.
Drawings
The utility model will be further described with reference to the accompanying drawings in which:
FIG. 1 is a schematic view of a catheter according to an embodiment of the present invention;
FIG. 2 is a cross-sectional view of a urinary catheter according to an embodiment of the present invention;
reference numerals: the main pipe 10, the first channel 11, the second channel 12, the first liquid outlet 121, the third channel 13, the second liquid outlet 131, the urine inlet 14, the first balloon 20, the second balloon 30, the first joint 40, the second joint 50, the third joint 60, and the plug 70.
Detailed Description
Reference will now be made in detail to the present preferred embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout.
In the description of the present invention, it should be understood that the orientation or positional relationship referred to in the description of the orientation, such as the upper, lower, front, rear, left, right, etc., is based on the orientation or positional relationship shown in the drawings, and is only for convenience of description and simplification of description, and does not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and thus, should not be construed as limiting the present invention.
In the description of the present invention, the meaning of a plurality of means is one or more, the meaning of a plurality of means is two or more, and larger, smaller, larger, etc. are understood as excluding the number, and larger, smaller, inner, etc. are understood as including the number. If the first and second are described for the purpose of distinguishing technical features, they are not to be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated or implicitly indicating the precedence of the technical features indicated.
In the description of the present invention, unless otherwise explicitly limited, terms such as arrangement, installation, connection and the like should be understood in a broad sense, and those skilled in the art can reasonably determine the specific meanings of the above terms in the present invention in combination with the specific contents of the technical solutions.
Referring to fig. 1 and 2, embodiments of the present invention provide a urinary catheter comprising: a main pipe 10, wherein a first channel 11 for catheterization is arranged in the main pipe 10; the first balloon 20 is fixed on the outer wall of the main pipeline 10, and a second channel 12 communicated with the first balloon 20 is arranged in the main pipeline 10 and used for conveying liquid medicines into the first balloon 20; the first connector 40 is connected with the second channel 12, and a liquid inlet of the first connector 40 is connected with an external infusion set; wherein, the wall of the first balloon 20 is a dialysis membrane for allowing the liquid medicine to enter the bladder of the human body through dialysis.
The catheter of this embodiment, insert patient's bladder preset position with the one end (the one end that is close to first sacculus 20) of main pipe 10, the urine is derived through first passageway 11 in the main pipe 10, in addition, can input the liquid medicine of relative high concentration to first sacculus 20 at any time through first joint 40 and second passageway 12, first sacculus 20 adopts the dialysis membrane, the medicine passes through dialysis and persistently gets into in the bladder to realize the controllable and active release of medicine, the kind and the input opportunity of medicine can be selected according to actual need.
Specifically, one end of the first channel 11 is provided with a urine inlet 14, and the other end of the first channel 11 is connected with a third connector 60, and is connected with a urine containing device such as a urine bag through the third connector 60. The second channel 12 has a first liquid outlet 121, and the first liquid outlet 121 is connected to the first balloon 20.
In this embodiment, different kinds of antibacterial liquid drugs are injected into the first balloon 20, and the different antibacterial liquid drugs have different functions, so that the probability of drug resistance of bacteria in the bladder can be effectively reduced, and the problem of infection of the postoperative urinary system of a patient can be effectively solved.
In some embodiments, the antibacterial liquid medicine comprises at least one of triclosan, sodium citrate, fluoxetine and pyrazothion, wherein triclosan is used as a broad-spectrum bactericide and can kill bacteria such as proteus mirabilis and pseudomonas aeruginosa; the sodium citrate can reduce the pH value of urine and inhibit the deposition of calcium carbonate and magnesium phosphate; fluoxetine and pyrazothion are used as bacterial efflux pump inhibitors and can inhibit the formation of bacterial membranes. Therefore, the antibacterial liquid medicine can effectively remove bacteria, prevent, relieve and clear bacterial membranes, reduce urine pH to inhibit crystallization, realize antibacterial and anti-crystallization, improve the problem that the existing catheter is easy to block and the current situation of disposable use, and greatly prolong the service life of the catheter.
Of course, it is understood that other drugs may be introduced as needed in addition to the above-described antibacterial liquid drugs to achieve the corresponding functions.
It is understood that the first balloon 20 may be provided in plural numbers as needed, and the plural second channels 12 and the first connectors 40 are provided accordingly, and different first balloons 20 may be inputted with the same kind of liquid medicine or different kinds of liquid medicines; in addition, the shape and size of the first balloon 20 are not limited to those shown in the drawings, and the balloon is not limited to a spherical shape, and is not to be construed as limiting the shape of the first balloon 20, and may be irregular in shape as long as it can contain a drug.
In some embodiments, the catheter further comprises a second balloon 30, the second balloon 30 is fixed on the outer wall of the main conduit 10, and a third channel 13 communicated with the second balloon 30 is arranged in the main conduit 10 and used for delivering gas or liquid into the second balloon 30, so that the second balloon 30 is inflated and fixed in the human bladder, thereby fixing the catheter. The third channel 13 has a second liquid outlet 131, and the second liquid outlet 131 is connected to the second balloon 30.
Further, the catheter also comprises a second connector 50, the second connector 50 being connected to the third channel 13. An external infusion set is connected through the second connector 50, specifically, in the present embodiment, the physiological saline is infused into the second balloon 30. Unlike the first balloon 20, the second balloon 30 is made of a non-dialysis membrane, so that the liquid in the second balloon 30 cannot enter the bladder of the patient.
In some embodiments, a plug 70 for sealing is further provided at the inlet of the first joint 40 and the second joint 50. When not in use, the first connector 40 and the second connector 50 are sealed by the plug 70 to avoid contaminating the inside of the first balloon 20 and the second balloon 30.
The embodiments of the present invention have been described in detail with reference to the accompanying drawings, but the present invention is not limited to the above embodiments, and various changes can be made within the knowledge of those skilled in the art without departing from the gist of the present invention.
Claims (7)
1. A urinary catheter, comprising:
the urethral catheterization device comprises a main pipeline, wherein a first channel for urethral catheterization is arranged in the main pipeline;
the first balloon is fixed on the outer wall of the main pipeline, and at least one second channel communicated with the first balloon is arranged in the main pipeline and used for conveying liquid medicines into the first balloon; and
at least one first connector connecting the respective second channels;
wherein, the capsule wall of the first sacculus is a dialysis membrane for leading the liquid medicine to enter the bladder of the human body through dialysis.
2. A urinary catheter according to claim 1, wherein: different antibacterial liquid medicines are injected into the first saccule.
3. A urinary catheter according to claim 2, wherein: the antibacterial liquid medicine comprises at least one of triclosan, sodium citrate, fluoxetine and pyrazothion, wherein the triclosan is used for killing proteus mirabilis and pseudomonas aeruginosa, the sodium citrate is used for reducing the pH of urine and inhibiting the deposition of calcium carbonate and magnesium phosphate, and the fluoxetine and the pyrazothion are used for inhibiting the formation of a bacterial membrane.
4. A catheter according to any of claims 1 to 3 wherein: the catheter also comprises a second balloon fixed on the outer wall of the main pipeline, and a third channel communicated with the second balloon is arranged in the main pipeline and used for conveying gas or liquid into the second balloon so as to enable the second balloon to be expanded and fixed in the bladder of the human body.
5. A catheter according to claim 4, wherein: the catheter further comprises a second connector, the second connector being connected to the third channel.
6. A catheter according to claim 5, wherein: and pipe plugs for sealing are arranged at the liquid inlets of the first joint and the second joint.
7. A urinary catheter according to claim 1, wherein: one end of the first channel is provided with a urine inlet, the other end of the first channel is connected with a third joint, and the third joint is used for being connected with a urine containing device.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202022939601.2U CN215461270U (en) | 2020-12-09 | 2020-12-09 | Catheter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202022939601.2U CN215461270U (en) | 2020-12-09 | 2020-12-09 | Catheter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN215461270U true CN215461270U (en) | 2022-01-11 |
Family
ID=79717365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202022939601.2U Active CN215461270U (en) | 2020-12-09 | 2020-12-09 | Catheter |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN215461270U (en) |
-
2020
- 2020-12-09 CN CN202022939601.2U patent/CN215461270U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11826539B2 (en) | Device for delivery of antimicrobial agent into a medical device | |
| US5049139A (en) | Apparatus for antimicrobial use | |
| AU2017397418B2 (en) | Catheter system for continuous irrigation | |
| US5141499A (en) | Peritoneal dialysis catheter | |
| US4623329A (en) | Drainage and infusion catheters having a capillary sleeve forming a reservoir for a fluid antimicrobial agent | |
| EP1694399B1 (en) | Device for administering therapeutic agents | |
| US11413376B2 (en) | Application of antimicrobial agents to medical devices | |
| JP2017502802A (en) | UV sterilization catheter and catheter connector | |
| CN215461270U (en) | Catheter | |
| WO2010041084A1 (en) | Medical device | |
| CN112089952A (en) | Non-coating antibacterial catheter | |
| CN212547923U (en) | Non-coating antibacterial catheter | |
| US20220369644A1 (en) | Antimicrobial composition and system for delivering an antimicrobial composition | |
| CN1964758B (en) | Device for administering therapeutic agents | |
| Christakis et al. | Antibiotic lock treatment of catheter-related sepsis | |
| Counts | CLAVE® Connector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: No. 1307, Guangzhou Avenue middle, Tianhe District, Guangzhou, Guangdong 510500 Patentee after: Institute of health medicine, Guangdong Academy of Sciences Address before: No. 1307, Guangzhou Avenue middle, Tianhe District, Guangzhou, Guangdong 510500 Patentee before: GUANGDONG INSTITUTE OF MEDICAL INSTRUMENTS |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240115 Address after: No.10, shiliugang Road, Haizhu District, Guangzhou City, Guangdong Province 510000 Patentee after: Institute of biological and medical engineering, Guangdong Academy of Sciences Address before: No. 1307, Guangzhou Avenue middle, Tianhe District, Guangzhou, Guangdong 510500 Patentee before: Institute of health medicine, Guangdong Academy of Sciences |
|
| TR01 | Transfer of patent right |